CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting
- Written by PR Newswire
![]() |
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology ("ASH") Annual Meeting, the Company presented one poster with study...
Read more: CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting















